Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Revenue: 2017-2025

Historic Revenue for Protagonist Therapeutics (PTGX) over the last 6 years, with Sep 2025 value amounting to $4.7 million.

  • Protagonist Therapeutics' Revenue rose 0.79% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.6 million, marking a year-over-year decrease of 35.12%. This contributed to the annual value of $434.4 million for FY2024, which is 624.05% up from last year.
  • Per Protagonist Therapeutics' latest filing, its Revenue stood at $4.7 million for Q3 2025, which was down 15.04% from $5.5 million recorded in Q2 2025.
  • Protagonist Therapeutics' Revenue's 5-year high stood at $255.0 million during Q1 2024, with a 5-year trough of -$19,000 in Q4 2022.
  • Its 3-year average for Revenue is $64.7 million, with a median of $16.9 million in 2025.
  • In the last 5 years, Protagonist Therapeutics' Revenue slumped by 100.22% in 2022 and then soared by 263,257.89% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Revenue (Quarterly) stood at $8.6 million in 2021, then plummeted by 100.22% to -$19,000 in 2022, then surged by 263,257.89% to $50.0 million in 2023, then spiked by 230.00% to $165.0 million in 2024, then grew by 0.79% to $4.7 million in 2025.
  • Its Revenue stands at $4.7 million for Q3 2025, versus $5.5 million for Q2 2025 and $28.3 million for Q1 2025.